Quantum SI (QSI) Q4 2025: Proteus Launch Price Set at $425K as Installed Base Drives 25% Consumables Growth
Quantum SI is intentionally sacrificing near-term hardware revenue to accelerate market readiness and adoption for its next-gen Proteus platform, with consumables utilization up more than 25% in its installed base. Management’s decision to announce Proteus’ $425,000 price point early is designed to secure capital budget allocations and grant inclusion, aiming for a robust commercial ramp in 2027. Investors should watch for continued R&D progress and customer engagement as QSI navigates a deliberate transition year.
Summary
- Consumables Utilization Surges: Installed base drove over 25% growth in consumable kit usage, offsetting weak hardware sales.
- Proteus Launch Readiness: Early price disclosure and channel engagement are moving customers into the 2027 adoption funnel.
- Strategic Trade-Offs Shape 2026: QSI is prioritizing long-term platform value over near-term revenue, signaling a multi-year inflection.
Business Overview
Quantum SI develops next-generation protein sequencing platforms, primarily serving academic, pharma, and biotech markets. The company generates revenue through instrument (hardware) sales, consumable kits, and related services. Its legacy Platinum and Platinum Pro systems established its installed base, while the upcoming Proteus platform, a high-throughput protein sequencing system, is positioned as the future growth engine. Consumables, recurring reagent and kit sales tied to instrument usage, are a key driver of ongoing revenue.
Performance Analysis
QSI’s Q4 2025 reflected the deliberate shift from hardware sales to consumables-driven revenue, as management deprioritized new instrument placements to prepare for Proteus’ launch. Capital sales headwinds persisted, with academic and pharma customers delaying major purchases in anticipation of the next-gen platform. Consumables utilization, however, increased by more than 25% among the installed base, signaling deeper customer engagement and higher recurring revenue potential.
Gross margin compressed in the quarter due to a higher mix of lower-margin consumables and inventory adjustments, a trend expected to persist through 2026. Operating expenses declined YoY on an adjusted basis, reflecting tighter cost controls and focused R&D on Proteus. The company ended the year with $215.8 million in cash and investments, supporting runway into 2028 despite forecasted top-line softness in 2026.
- Consumables-Driven Revenue Mix: Over 25% growth in consumable kit usage, with minimal new hardware placements expected in 2026.
- Gross Margin Headwind: Consumables and deferred hardware revenue credits are diluting margin structure versus prior periods.
- Cost Discipline Maintained: Adjusted operating expenses fell YoY, with R&D spend tightly focused on Proteus milestones.
QSI’s financials reflect a company in purposeful transition, with recurring consumables revenue and R&D progress providing the foundation for Proteus’ commercial ramp in 2027.
Executive Commentary
"We expect that 2026 will be a transition year with revenue primarily driven by consumable utilization from our installed base and some new placements, very modest new capital sales, and a laser focus on Proteus development and preparing the market for a strong commercial ramp in 2027 and beyond."
Jeff Hawkins, President and Chief Executive Officer
"We are making intentional choices that prioritize long-term platform adoption over near-term revenue maximization. This includes embedding upgrade paths into Platinum Pro units, which has a near-term revenue impact, as well as impacts of customer-delayed purchases as they plan for Proteus."
Jeff Kyes, Chief Financial Officer
Strategic Positioning
1. Installed Base Monetization and Market Development
QSI’s placement program has secured 17 new customers, giving key opinion leaders hands-on experience with its technology ahead of Proteus. The company is leveraging this installed base to drive consumables revenue and build a publication pipeline, priming the market for future adoption.
2. Early Proteus Price Disclosure and Customer Budgeting
Announcing the $425,000 Proteus list price nearly a year ahead of launch is a strategic move, enabling customers to include the instrument in grant applications and capital budgets. This approach is designed to ensure QSI is positioned for early adoption as soon as Proteus becomes commercially available.
3. Innovation Roadmap and Application Expansion
Proteus’ technical progress has exceeded expectations, with detection of 18 amino acids at launch and the prospect of all 20 within the year. Expanded read length and sample prep advances are unlocking new clinical and translational research applications, broadening addressable markets.
4. Channel Partner and Global Market Readiness
QSI is leveraging a global channel partner network, with upcoming meetings to refine market targeting for Proteus. The company is also evaluating partnership opportunities in sample enrichment and AI-driven analytics to further differentiate its platform.
5. Financial Flexibility and Cost Structure Adaptation
With $215.8 million in cash and investments, QSI can fund Proteus development, commercial buildout, and ongoing operations through 2028, while retaining flexibility to reallocate R&D spend post-launch toward commercialization or other strategic initiatives.
Key Considerations
QSI’s 2026 is defined by deliberate trade-offs, with near-term revenue and margin compression accepted in favor of long-term platform positioning and customer engagement. The company’s strategic choices reflect a commitment to capturing a larger share of the protein sequencing market as Proteus comes online.
Key Considerations:
- Consumables Utilization Ramp: Recurring revenue from consumables is now the primary growth lever, with customer usage up over 25% YoY.
- Proteus Budget Inclusion: Early price disclosure is aimed at securing capital allocations and grant funding for 2027 adoption.
- Margin Structure Under Pressure: Lower-margin consumables and deferred hardware revenue credits will weigh on gross margins in 2026.
- R&D Focus on Launch Readiness: All development resources are dedicated to Proteus, with technical risk largely retired and integration/manufacturing the main gating factors.
- Balance Sheet Strength: Ample liquidity allows QSI to execute its transition strategy without near-term capital constraints.
Risks
QSI’s transition year exposes it to several risks: Prolonged capital market headwinds, NIH funding volatility, and slower-than-expected Proteus adoption could delay revenue inflection. Margin compression from consumables mix and deferred revenue may persist longer if hardware sales remain sluggish. Execution risk remains around Proteus’ final integration, manufacturing scale-up, and post-launch support, though technical risk is now largely behind the company.
Forward Outlook
For 2026, Quantum SI guided to:
- Total revenue of approximately $1 million, reflecting minimal hardware sales and a focus on consumables.
- Adjusted operating expenses of $98 million or less, with total cash usage capped at $93 million.
For full-year 2026, management maintained a focus on:
- Completing Proteus development and commercial readiness for a late 2026 launch.
- Expanding installed base engagement and consumable usage.
Management highlighted deliberate trade-offs, emphasizing long-term adoption over short-term revenue, and expects to provide quantitative updates on Proteus milestones throughout the year.
Takeaways
QSI is sacrificing near-term optics for long-term platform value, with consumables growth and R&D progress as leading indicators for Proteus’ commercial trajectory.
- Consumables Momentum: Over 25% usage growth in the installed base validates market engagement and recurring revenue potential.
- Proteus Launch Preparation: Early price setting and customer engagement are designed to secure a strong launch curve and accelerate adoption in 2027.
- Execution Watchpoint: Investors should monitor Proteus’ integration, manufacturing, and early market feedback as the critical determinants of the next phase of growth.
Conclusion
Quantum SI’s Q4 2025 marks a pivotal transition, with the company making disciplined, long-term bets on Proteus and recurring consumables revenue. The next twelve months will test QSI’s ability to convert technical progress and early customer engagement into a successful commercial launch and sustainable growth trajectory.
Industry Read-Through
QSI’s transition year and early price disclosure for Proteus signal a broader shift in the life science tools sector toward recurring consumables models and multi-year platform adoption cycles. Capital sales headwinds and funding volatility remain industry-wide challenges, with vendors increasingly focused on securing budget allocations well ahead of launch. Competitive differentiation through technical innovation, application breadth, and channel strategy is becoming more pronounced, with recurring revenue and customer engagement emerging as the key valuation levers for next-generation platform players.